![]() |
產(chǎn)地 | 進(jìn)口、國(guó)產(chǎn) |
品牌 | 上海莼試 |
保存條件 | Store at -20 °C |
貨號(hào) | CS9702 |
應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
CAS編號(hào) | |
抗體名 | Anti-NIRF |
克隆性 | |
靶點(diǎn) | 詳見(jiàn)說(shuō)明書(shū) |
適應(yīng)物種 | 詳見(jiàn)說(shuō)明書(shū) |
形態(tài) | 詳見(jiàn)說(shuō)明書(shū) |
宿主 | 詳見(jiàn)說(shuō)明書(shū) |
亞型 | IgG |
標(biāo)識(shí)物 | 詳見(jiàn)說(shuō)明書(shū) |
濃度 | 1mg/1ml% |
免疫原 | KLH conjugated synthetic peptide derived from hu NIRF/RNF107 |
產(chǎn)品訂購(gòu)信息:
英文名稱 Anti-NIRF
中文名稱 環(huán)指蛋白107抗體規(guī)格
別 名 E3 ubiquitin-protein ligase UHRF2; Np95 like RING finger protein; Np95-like ring finger protein; Np95/ICBP90 like RING finger protein; Np95/ICBP90-like RING finger protein; Nuclear protein 97; Nuclear zinc finger protein Np97; RING finger protein 107; RNF 107; RP11-472F14.2; Ubiquitin like containing PHD and RING finger domains protein 2; Ubiquitin-like PHD and RING finger domain-containing protein 2; Ubiquitin-like-containing PHD and RING finger domains protein 2; Uhrf2; UHRF2_HUMAN.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來(lái)源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Dog, Cow
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 細(xì)胞周期蛋白 鋅指蛋白
蛋白分子量 predicted molecular weight: 90kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from hu NIRF/RNF107
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
環(huán)指蛋白107抗體規(guī)格 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
(石蠟切片需做抗原修復(fù))
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 E3 ubiquitin-protein ligase which mediates ubiquitination and subsequent proteasomal degradation of PCNP. May participate in methylation-dependent transcriptional regulation. Important for G1/S transition. Overexpression causes G1 phase cell arrest.
Function : E3 ubiquitin-protein ligase that is an intermolecular hub protein in the cell cycle network. Through cooperative DNA and histone binding, may contribute to a tighter epigenetic control of gene expression in differentiated cells. Ubiquitinates cyclins, CCND1 and CCNE1, in an apparently phosphorylation-independent manner and induces G1 arrest. Also ubiquitinates PCNP leading to its degradation by the proteasome. E3 SUMO-, but not ubiquitin-, protein ligase for ZNF131.Subunit : Homodimer; disulfide-linked. Binds methylated CpG containing oligonucleotides. Interacts with H3: the interaction has a preference for the 'Lys-9' trimethylated form of H3 (H3K9me3) (By similarity). Interacts with PCNP, HDAC1 and CDK2 (inactive form). Component of a complex at least composed of UHRF2, CDK2 and CCNE1. Interacts directly with CCNE1; the interaction ubiquitinates CCNE1 and appears independent of CCNE1 phosphorylation. Interacts with CCND1; the interaction ubiquitinates CCND1 and appears independent of CCND1 phosphorylation. Interacts with p53/TP53 and RB1. Interacts with UBE2I.Subcellular Location : Nucleus. Note=Enriched at pericentric heterochromatin (PH). This localization is dependent on the interaction with H3K9me3 (By similarity).Post-translational modifications : May be autoubiquitinated; which may lead to proteasomal degradation.Phosphorylated. Phosphorylation may be mediated by CDK2.Autosumoylated.DISEASE : Note=Associated with various cancers. DNA copy number loss is found in multiple kinds of malignancies originating from the brain, breast, stomach, kidney, hematopoietic tissue and lung.Similarity : Contains 1 PHD-type zinc finger.Contains 1 RING-type zinc finger.Contains 1 ubiquitin-like domain.Contains 1 YDG domain.Database links : UniProtKB/Swiss-Prot: Q96PU4.1
A/H1N1-M2 Human(Avian influenza Matrix Protein-2 Human) A型人病毒H1N1-M2蛋白多肽Multi-class antibodies規(guī)格: 0.5mg
SERPINF2 SerpinF2 兔單抗 (PE) Human
Rhesus antibody Rh phospho-CREB-1(Ser129) 磷酸化CREB-1抗體 規(guī)格 0.1ml
淋巴細(xì)胞分離液(小鼠、大鼠、豬、兔等) 250ml
zbtb11 英文名稱: 鋅指蛋白913抗體 0.2ml
Dab1 英文名稱: 磷脂蛋白受體Dab1抗體 0.1ml
SERPINF2 SerpinF2 兔單抗 (PE) Human
URGCP/URG4(Up-regulator of cell proliferation) 病毒X蛋白(HBxAg)抗原Multi-class antibodies規(guī)格: 0.5mg
Anti-Beta-Actin β-肌動(dòng)蛋白抗體(內(nèi)參抗體)Multi-class antibodies規(guī)格: 0.1ml
Rhesus antibody Rh phospho-c-Raf(Ser259) 磷酸化原癌基因c-Raf抗體 規(guī)格 0.1ml
兔抗大鼠IgG純化抗體 1mg/10mg 國(guó)產(chǎn)
YAP1 英文名稱: 原癌基因Yes相關(guān)蛋白1抗體 0.2ml
DPYD 英文名稱: 二氫嘧啶脫氫酶抗體 0.2ml
Anti-Beta-Actin β-肌動(dòng)蛋白抗體(內(nèi)參抗體)Multi-class antibodies規(guī)格: 0.1ml
SHARPIN 英文名稱: 線性泛素鏈相關(guān)蛋白SHARPIN抗體 0.2ml
Epsin 1 英文名稱: 內(nèi)吞作用輔助蛋白EPN1抗體 0.2ml
細(xì)胞周期調(diào)控因子34 Anti-Cdc34 0.1ml
Anti-Visfatin-2(CT)/FITC 熒光素標(biāo)記內(nèi)脂素/內(nèi)臟脂肪素(C端抗體)IgGMulti-class antibodies規(guī)格: 0.2ml
Rhesus antibody Rh phospho-GAB2 (Tyr643) 磷酸化接頭蛋白Gab2抗體 規(guī)格 0.1ml
CK14/17/42/10 peptide 細(xì)胞角蛋白14抗原Multi-class antibodies規(guī)格: 0.5mg
H2STestMediumAgar
FWA淡水魚(yú)類瓊脂培養(yǎng)基 250g 用于淡水魚(yú)類腸道內(nèi)細(xì)菌檢測(cè)
李氏菌選擇性培養(yǎng)基基礎(chǔ)(MMA) Modified Mcbride Agar Base 250 用于單增李氏菌選擇性分離(SN標(biāo)準(zhǔn))
胰酪胨大豆肉湯250g/瓶用于金黃色葡萄球菌的增菌和MPN試驗(yàn)incubationmedia胰酪胨大豆肉湯250g/瓶用于金黃色葡萄球菌的增菌和MPN試驗(yàn)
即用型管裝培養(yǎng)基
TrypticaseSoy-YeastExtractBroth
酪蛋白瓊脂 Casein Agar 用于蠟樣芽孢桿菌的酪蛋白分解試驗(yàn)
卵黃甘露醇高鹽瓊脂基礎(chǔ) Egg-Yolk Mannitol Salt Agar Base 250克 金黃色葡萄球菌的分離培養(yǎng)
2×YT培養(yǎng)基250g/瓶用于重組大腸桿菌菌株的培養(yǎng)incubationmedia2×YT培養(yǎng)基250g/瓶用于重組大腸桿菌菌株的培養(yǎng)
腸球菌、溶血性鏈球菌和糞鏈球菌檢驗(yàn)培養(yǎng)基
環(huán)指蛋白107抗體規(guī)格 奈瑟氏菌屬細(xì)菌生化鑒定盒 規(guī)格: 8種×10次/盒 用途: 用于奈瑟氏菌屬細(xì)菌生化鑒定
霍亂弧菌生化鑒定盒 規(guī)格: 11種×10次 用途: 霍亂弧菌生化鑒定
弧菌科細(xì)菌生化鑒定盒(16種×5次) 規(guī)格: 16種×5次 用途: 弧菌的生化鑒定
麥?zhǔn)媳葷峁?nbsp; 規(guī)格: 1套/盒 用途:
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn):
1. 環(huán)指蛋白107抗體規(guī)格 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析;
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來(lái)篩選最適條件;
3.用NHSB量過(guò)量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活;
4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等;
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性;
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及*基,也可與糖基共價(jià)結(jié)合;
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用;
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定:
1)環(huán)指蛋白107抗體規(guī)格 抗體的效價(jià)鑒定:不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來(lái)鑒定。
2)抗體的特異性鑒定:抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力??贵w的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來(lái)表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無(wú)窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3)抗體親和力:是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫(kù)侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol??贵w親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。